KemPharm, Inc. (NASDAQ:KMPH – Get Rating) was the target of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 1,450,000 shares, a growth of 5.8% from the January 15th total of 1,370,000 shares. Approximately 4.6% of the company's shares are sold short. Based on an average trading volume of 243,900 shares, the days-to-cover ratio is presently 5.9 days.
Insider Buying and Selling
In other news, CEO Richard W. Pascoe acquired 9,500 shares of KemPharm stock in a transaction that occurred on Friday, January 13th. The shares were acquired at an average price of $5.44 per share, with a total value of $51,680.00. Following the purchase, the chief executive officer now directly owns 19,973 shares of the company's stock, valued at $108,653.12. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.10% of the stock is owned by insiders.
Get
KemPharm alerts:
Institutional Investors Weigh In On KemPharm
Institutional investors have recently modified their holdings of the business. UBS Group AG bought a new stake in shares of KemPharm in the second quarter valued at about $26,000. Verition Fund Management LLC acquired a new position in KemPharm in the fourth quarter valued at about $46,000. Invesco Ltd. acquired a new position in KemPharm in the first quarter valued at about $51,000. Kingsview Wealth Management LLC acquired a new position in KemPharm in the second quarter valued at about $54,000. Finally, Atom Investors LP acquired a new position in KemPharm in the third quarter valued at about $88,000. Institutional investors own 19.39% of the company's stock.
Wall Street Analyst Weigh In
KMPH has been the topic of several research analyst reports. StockNews.com upgraded shares of KemPharm from a "sell" rating to a "hold" rating in a report on Saturday, November 19th. Cantor Fitzgerald started coverage on shares of KemPharm in a report on Thursday, November 17th. They set an "overweight" rating and a $20.00 target price on the stock. Finally, Canaccord Genuity Group lowered their target price on shares of KemPharm from $20.00 to $19.00 in a report on Thursday, November 10th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $17.25.
KemPharm Price Performance
Shares of KemPharm stock traded down $0.05 during trading on Thursday, reaching $5.34. The company's stock had a trading volume of 12,042 shares, compared to its average volume of 194,806. The business's 50-day moving average price is $5.07 and its 200-day moving average price is $5.40. KemPharm has a 52 week low of $4.00 and a 52 week high of $6.92. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.14.
KemPharm Company Profile
(Get Rating)
KemPharm, Inc is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy.
Recommended Stories
- Get a free copy of the StockNews.com research report on KemPharm (KMPH)
- Cisco Systems Is Ready To Run Higher
- Affirm: How To Still Make Money Here
- What Should Investors Make of These Large Cap Penny Stocks?
- Roblox Gains Traction With Metaverse, Shares Pop
- GXO Logistics Manages Another Buying Opportunity
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.
